Research programme: gene therapeutics - Code Biotherapeutics
Latest Information Update: 28 Apr 2021
At a glance
- Originator Code Biotherapeutics
- Class Diabetes gene therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Duchenne muscular dystrophy; Type 1 diabetes mellitus
Most Recent Events
- 20 Apr 2021 Research programme: gene therapeutics - Code Biotherapeutics is available for licensing as of 20 Apr 2021. https://www.codebiotx.com/
- 20 Apr 2021 Early research in Duchenne muscular dystrophy in USA (unspecified route)
- 20 Apr 2021 Early research in Type 1 diabetes mellitus in USA (unspecified route)